Cellectar Biosciences
CLRB
24 hedge funds and large institutions have $3.22M invested in Cellectar Biosciences in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
50% more capital invested
Capital invested by funds: $2.14M → $3.22M (+$1.08M)
20% more funds holding
Funds holding: 20 → 24 (+4)
0.33% more ownership
Funds ownership: 0.35% → 0.67% (+0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.51M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$589K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$332K |
| 4 |
Renaissance Technologies
New York
|
+$58K |
| 5 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$40K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Difesa Capital Management
New York
|
-$34K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$1K |
| 3 |
Bank of New York Mellon
New York
|
-$180 |
CLRB Hedge Fund Activity: Q4 2022 in Review
24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2022, worth a combined $3.22M — up 50% from $2.14M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CLRB positions and 1 closed out — a net gain of 5 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $1.51M. The largest seller was Difesa Capital Management, exiting entirely with an estimated $34K sold.
- 24 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2022, up from 20 in Q3 2022.
- Funds reported $3.22M of Cellectar Biosciences stock for Q4 2022, up 50% quarter-over-quarter.
- 6 funds opened new Cellectar Biosciences positions in Q4 2022 and 1 closed out, a net change of +5 holders.
- The largest Cellectar Biosciences buyer in Q4 2022 was AIGH Capital Management, an estimated $1.51M added.
- The largest Cellectar Biosciences seller in Q4 2022 was Difesa Capital Management, an estimated $34K sold.
Based on aggregated 13F filings for Q4 2022.